Home/Pipeline/ERNA-201

ERNA-201

Rheumatoid Arthritis

PreclinicalActive Discovery/Research

Key Facts

Indication

Rheumatoid Arthritis

Phase

Preclinical

Status

Active Discovery/Research

Company

Eterna Therapeutics

About Eterna Therapeutics

Eterna Therapeutics is advancing a pipeline of allogeneic, synthetic cell therapies targeting high-need areas in oncology and autoimmune diseases. The company's core technology engineers iPSC-derived mesenchymal stem cells (iMSCs) to function as targeted delivery vehicles for cytokines like IL-7/IL-15 and IL-10 directly to disease sites. With lead candidate ERNA-101 advancing towards the clinic for platinum-resistant ovarian cancer, the company's strategy focuses on demonstrating proof-of-concept in a challenging indication with significant unmet need, while leveraging a scalable platform for broader applications. Eterna operates as a public company, trading on the NASDAQ under the ticker ERNA.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Rheumatoid Arthritis Drugs

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
Piclidenoson (CF101)	Can Fite Biopharma	Phase II/III	Previously Active
Tc99m Tilmanocept	Navidea Biopharmaceuticals	Phase 2/3	Jeopardized (Bankruptcy)
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)
EYD-001 (Takinib analog)	EydisBio	Preclinical	In vivo efficacy and pilot safety in progress
LFD-200	Lifordi Immunotherapeutics	Phase 1	Active
MEV-N01	Mesenbio	Pre-clinical	Active
CIT-013	Citryll	Phase 2a	Active
Restem-L	Restem	Phase 2	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active
AX-158	Artax Biopharma	Phase 2	Active
Rheumatoid Arthritis Therapy Guidance Test	Aqtual	Pre-clinical/Clinical Study	Active